May 23, 2022 8:00 am EDT CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
May 12, 2022 4:06 pm EDT CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022 8:00 am EDT CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022
May 05, 2022 4:01 pm EDT CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022
Apr 04, 2022 8:00 am EDT CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis
Mar 17, 2022 4:06 pm EDT CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update
Mar 10, 2022 4:05 pm EST CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022
Nov 18, 2021 8:00 am EST CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants